6/1/2018
`
`Corporate
`
`
`
`Global glaucoma market to reach $3.8bn by 2026 | GlobalData Plc
`
`+
`Careers (https://www.globaldata.com/careers/)
`Contact (https://www.globaldata.com/contact-us/)
` (https://www.globaldata.com/)
`+
`+
`Subscribe (https://www.globaldata.com/#switch1)
`Investor Center (https://www.globaldata.com/investor-centre/)
`Media Centre (https://www.globaldata.com/media-centre/)
`Client Login (https://www.globaldata.com/client-login/)
`Report Store (https://www.globaldata.com/store)
`
` (/index.php)
`
` (/client-login/)
`
`(https://www.globaldata.com/store)
`
`February 1, 2018 /
`
`
`
`PrePress ss RelRe ease / Healthcare (/media-centrere/?_/?_sftsft_by_by-in-indusdustrytry=he=healtalthcahcare)re)( _ _ y yy
`
`Global glaucoma market to reach $3.8bn by 2026
`
`
`
`
`
`By GlobalData Healthcare (/media-centre/?_sft_by-industry=healthcare)
`
`Tagged: Drug Treatment (https://www.globaldata.com/tag/drug-treatment/) / Eye Disease (https://www.globaldata.com/tag/eye-disease/) /
`Glaucoma (https://www.globaldata.com/tag/glaucoma/) / Healthcare (https://www.globaldata.com/tag/healthcare/)
`
`The total glaucoma market was estimated to be $2.6bn across the seven major markets (7MM*) in 2016.
`This is expected to grow to $3.8bn in 2026, at a Compound Annual Growth Rate (CAGR) of 4.1%,
`according to GlobalData, a leading data and analytics company.
`
`The company’s latest report:
`‘PharmaPoint: Glaucoma’ (https://www.globaldata.com/store/report/gdhc158pidr--pharmapoint-glaucoma-global-drug-
`forecast-and-market-analysis-to-2026/?
`utm_source=mediacenter&utm_medium=pr&utm_campaign=180201a_gd_ph_pr_glaucoma_market_2026&utm_nooveride=1)
`revealed that this growth will be driven by the launch of pipeline products. GlobalData anticipates that five products in the late-stage
`pipeline will enter the glaucoma market during the forecast period. These products include a first-in-class drug Santen’s DE-117 as
`well as one drug with an undisclosed MOA. Aerie’s fixed-dose combination therapy, Roclatan, and two sustained-release (SR)
`implants are also set to launch during the forecast period.
`
`https://www.globaldata.com/global-glaucoma-market-reach-3-8bn-2026/
`
`Micro Labs Exhibit 1055
`Micro Labs v. Santen Pharm. and Asahi Glass
`1/5
`IPR2017-01434
`
`

`

`6/1/2018
`
`Global glaucoma market to reach $3.8bn by 2026 | GlobalData Plc
`
`Thomas Moore, Healthcare Analyst at GlobalData, comments: “The late-stage pipeline drugs are set to have a significant impact on
`the glaucoma market, and be a key driver of growth throughout the forecast period. GlobalData forecasts that two pipeline
`products, Aerie’s Roclatan and Allergan’s Bimatoprost SR, will become the most successful drugs in the glaucoma market, with
`sales of $631.9M and $609.5M, respectively. Overall, GlobalData predicts that drugs that launch during the forecast period will
`account for 41% of the global glaucoma market in 2026.”
`
`Since 2014, the focus of pharmaceutical companies has begun to shift towards the development of new classes of glaucoma drugs,
`and this trend is expected to continue throughout the forecast period. Kowa’s Glanatec (ripasudil), launched in Japan in 2014, was
`the first Rho kinase inhibitor in the 7MM, and the first new class of glaucoma drug since Pfizer’s Xalatan launched in 1996. The
`glaucoma pipeline is set to continue this trend, with the recent approval of Valeant’s Vyzulta (latanoprostene bunod) and Aerie
`Pharmaceuticals’ Rhopressa (netarsudil) providing new classes of glaucoma drugs to ophthalmologists in the US.
`
`Moore continues: “Some pharmaceutical companies have opted to continue the established strategy of reformulating existing drugs
`for glaucoma to provide added value. In particular, there are two late-stage pipeline products, Ocular Therapeutix’s OTX-TP and
`Allergan’s Bimatoprost SR, which contain established prostaglandin analogues reformulated into an SR implant. These products
`are set to address poor patient adherence in glaucoma patients, and are expected to have a significant impact on the glaucoma
`market.”
`
`Glaucoma is an established indication with a large number of treatment options available, and as a result the disease is generally
`associated with low levels of unmet need. However, some unmet need does remain in this disease area, with the most significant
`generally considered to be a need for greater patient compliance.
`
`Moore adds: “The importance of the unmet need for greater compliance is reflected in the late-stage pipeline, which contains
`several products poised to help meet this unmet need. Specifically, there are two SR implants, Ocular Therapeutix’s OTX-TP and
`Allergan’s Bimatoprost SR, which will deliver drugs directly into the eye over several months, and thus avoid potential issues of
`https://www.globaldata.com/global-glaucoma-market-reach-3-8bn-2026/
`2/5
`
`Micro Labs Exhibit 1055-2
`
`

`

`non-compliance associated with topical medicines.”
`6/1/2018
`Global glaucoma market to reach $3.8bn by 2026 | GlobalData Plc
`
`* 7MM seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
`
`Information based on GlobalData’s report:
`PharmaPoint: Glaucoma – Global Drug Forecast and Market Analysis to 2026
`(https://www.globaldata.com/store/report/gdhc158pidr--pharmapoint-glaucoma-global-drug-forecast-and-market-analysis-to-
`2026/?
`utm_source=mediacenter&utm_medium=pr&utm_campaign=180201b_gd_ph_pr_glaucoma_market_2026&utm_nooveride=1)
`
`Want more Insight like this?
`Our interactive subscription platform has the most comprehensive data and analysis in your industry.
`
`Request a Demo
`
`How can we help your business?
`Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual
`requirements.
`
`Request a Callback (/contact-us/)
`
`Related Media
`
`https://www.globaldata.com/global-glaucoma-market-reach-3-8bn-2026/
`
`3/5
`
`Micro Labs Exhibit 1055-3
`
`

`

`6/1/2018
`
`Global glaucoma market to reach $3.8bn by 2026 | GlobalData Plc
`
`Stay informed with the latest analysis & insight direct to your inbox
`
`First name
`
`last name
`
`Email address
`https://www.globaldata.com/global-glaucoma-market-reach-3-8bn-2026/
`
`4/5
`
`Micro Labs Exhibit 1055-4
`
`

`

`6/1/2018
`Select your option
`
`Global glaucoma market to reach $3.8bn by 2026 | GlobalData Plc
`
`Please accept the
`
`terms of service and privacy policy (https://www.globaldata.com/privacy-policy/)
`
`I'm not a robot
`
`reCAPTCHA
`Privacy - Terms
`
`Subscribe
`
`Media Enquiries
`If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.
`
`pr@globaldata.com (mailto:pr@globaldata.com)
`EMEA: +44 207 832 4399
`APAC: +91 40 6616 6809
`contact online (/media-enquiries/)
`
`56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends…
`https://t.co/wJOJOqYIJF (https://t.co/wJOJOqYIJF) 3 hours ago
`
`Terms & Conditions (https://www.globaldata.com/terms-
`conditions/)
`
`Legal Disclaimer (/legal-
`disclaimer/)
`
`Privacy Policy
`(https://www.globaldata.com/privacy-policy/)
`
`Contact
`(https://www.globaldata.com/contact-us/)
`
`Sitemap
`(https://www.globaldata.com/sitemap/)
`
` (https://twitter.com/globaldataplc)
`
` (https://www.linkedin.com/company/globaldataplc)
`
` (https://twitter.com/globaldataplc)
`
` (https://www.linkedin.com/company/globaldataplc)
`
`© GlobalData Plc 2018 | Registered Office: John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK Registered in England No. 03925319
`
`This site uses cookies: Find out more. (https://www.globaldata.com/cookie-policy/)
`
`Okay, thanks
`
`(/)
`
`https://www.globaldata.com/global-glaucoma-market-reach-3-8bn-2026/
`
`5/5
`
`Micro Labs Exhibit 1055-5
`
`